Latest Breaking News On - Francei january - Page 1 : comparemela.com

OSE Immunotherapeutics Announces Acceptance of the US Investigational New Drug (IND) Application Obtained by Veloxis Pharmaceuticals, Inc., its Partner in Transplantation, for CD28 Antagonist VEL-101/FR104

United statesNorth carolinaDominique costantiniAsahi kaseiAsahi kasei groupNantes university hospitalVeloxis pharmaceuticals incBoehringer ingelheimFood drug administrationAnnounces acceptanceNew drugApplication obtainedVeloxis pharmaceuticalsFrancei januaryDrug administrationChief executive officer